Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
GRFS Grifols	$10.16 +0.8%	$9.78	$6.19 ▼ $11.14	$6.93B	0.56	1.19 million shs	759,888 shs
OCUL Ocular Therapeutix	$12.30 +1.4%	$10.91	$5.78 ▼ $12.91	$2.11B	1.49	2.10 million shs	1.41 million shs
ROIV Roivant Sciences	$11.92 +0.9%	$11.43	$8.73 ▼ $13.06	$8.03B	1.15	4.41 million shs	4.90 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+27.55%	+36.59%
GRFS Grifols	+0.79%	-5.22%	+3.15%	+25.28%	+32.46%
OCUL Ocular Therapeutix	+1.40%	-2.54%	+2.84%	+68.49%	+33.26%
ROIV Roivant Sciences	+0.93%	+0.59%	+4.65%	+9.66%	+1.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	0.4818 of 5 stars	2.1	0.0	0.0	0.0	0.0	0.8	0.6
GRFS Grifols	3.5703 of 5 stars	1.3	3.0	2.5	0.0	2.6	0.0	5.0
OCUL Ocular Therapeutix	4.1028 of 5 stars	3.5	3.0	0.0	4.1	2.8	1.7	0.0
ROIV Roivant Sciences	3.4381 of 5 stars	3.6	3.0	0.0	0.0	4.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.11	Hold	$130.00	0.42% Upside
GRFS Grifols	2.60	Moderate Buy	$10.30	1.38% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	39.84% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	38.42% Upside

Current Analyst Ratings Breakdown

Latest OCUL, BPMC, ROIV, and GRFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	GRFS Grifols	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	GRFS Grifols	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/17/2025	GRFS Grifols	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.60 ➝ $10.30
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
GRFS Grifols	$7.81B	0.89	$0.94 per share	10.77	$12.55 per share	0.81
OCUL Ocular Therapeutix	$63.72M	33.59	N/A	N/A	$1.76 per share	6.99
ROIV Roivant Sciences	$29.05M	278.94	N/A	N/A	$7.08 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	10/28/2025 (Estimated)
GRFS Grifols	$169.80M	$1.17	8.68	9.68	0.34	N/A	N/A	N/A	11/5/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	N/A
ROIV Roivant Sciences	-$171.98M	-$0.70	N/A	N/A	N/A	-2,111.79%	-15.90%	-14.95%	11/11/2025 (Estimated)

Latest OCUL, BPMC, ROIV, and GRFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.14	1.38%	N/A	11.97%	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Latest OCUL, BPMC, ROIV, and GRFS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	GRFS Grifols	--	$0.1404		8/12/2025	8/12/2025	8/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
GRFS Grifols	1.20	2.64	0.95
OCUL Ocular Therapeutix	0.23	10.10	10.02
ROIV Roivant Sciences	N/A	40.54	40.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
GRFS Grifols	N/A
OCUL Ocular Therapeutix	59.21%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
GRFS Grifols	0.19%
OCUL Ocular Therapeutix	2.30%
ROIV Roivant Sciences	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
ROIV Roivant Sciences	860	679.81 million	606.39 million	Optionable

OCUL, BPMC, ROIV, and GRFS Headlines

Recent News About These Companies

Eric Venker Sells 100,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

August 23 at 8:41 AM | insidertrades.com

Rep. Lisa C. McClain Purchases Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

August 23 at 5:05 AM | marketbeat.com

Charles Schwab Investment Management Inc. Grows Position in Roivant Sciences Ltd. $ROIV

August 22 at 3:27 AM | marketbeat.com

Nuveen LLC Takes $31.99 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

August 19, 2025 | marketbeat.com

Swiss National Bank Sells 22,100 Shares of Roivant Sciences Ltd. $ROIV

August 19, 2025 | marketbeat.com

Timeless Rajeev Ram wins Cincinnati Open, Vivek Ramaswamy recalls playing with USA star

August 18, 2025 | msn.com

Invesco Ltd. Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

August 18, 2025 | marketbeat.com

Citigroup Inc. Acquires 81,482 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

August 18, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Vanguard Group Inc. Has $411.35 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

August 17, 2025 | marketbeat.com

Entropy Technologies LP Purchases Shares of 99,973 Roivant Sciences Ltd. (NASDAQ:ROIV)

August 13, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Down Following Weak Earnings

August 12, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Announces Earnings Results, Misses Estimates By $0.07 EPS

August 12, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Down After Earnings Miss

August 12, 2025 | americanbankingnews.com

Why Roivant Sciences Stock Was Slipping on Monday

August 11, 2025 | fool.com

Roivant Sciences Ltd. 2025 Q1 - Results - Earnings Call Presentation

August 11, 2025 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

August 11, 2025 | zacks.com

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 11, 2025 | globenewswire.com

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

August 8, 2025 | investing.com

An Overview of Exact Sciences's Earnings

August 5, 2025 | benzinga.com

Roivant Sciences (ROIV) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, BPMC, ROIV, and GRFS Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Grifols NASDAQ:GRFS

$10.16 +0.08 (+0.79%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.14 -0.02 (-0.20%)

As of 08/22/2025 04:06 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Ocular Therapeutix NASDAQ:OCUL

$12.30 +0.17 (+1.40%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.30 0.00 (0.00%)

As of 08/22/2025 06:36 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.92 +0.11 (+0.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.78 -0.14 (-1.17%)

As of 08/22/2025 07:34 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time